Nephrol Dial Transplant (2003) 18: 2415-2420
© 2003 European Renal Association-European Dialysis and Transplant Association
Preliminary Communication
Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study
1Division of Nephrology, 2Department of Pathology, 5Department of Physiology and 6Department of Cardiovascular Medicine, University of Michigan, 3University Renal Research and Education Institute, Ann Arbor, MI and 4University of Massachusetts at Lowell, Boston, MA, USA
Correspondence and offprint requests to: Rajiv Saran, MD MS, Assistant Professor, Division of Nephrology, University of Michigan, Kidney Epidemiology and Cost Center, 315 West Huron, Suite 240, Ann Arbor, MI 48103-4262, USA. Email: rsaran{at}umich.edu
Background. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide synthase and a proposed cardiovascular risk factor, is elevated in chronic kidney disease (CKD). Pharmacological strategies that lower plasma concentration of ADMA may be expected to increase nitric oxide (NO·) bioavailability and potentially limit atherosclerosis. We hypothesized that the antioxidant 
-tocopherol (vitamin E) reduces ADMA levels in CKD.
Methods. An open-label pilot interventional study using 800 IU of vitamin E was undertaken in eight stable out-patients with non-diabetic CKD (creatinine clearance <30 ml/min/1.73 m2) and six healthy controls, with the objective of measuring plasma ADMA levels at baseline and after 8 weeks of treatment. Plasma ADMA, symmetric dimethylarginine (SDMA) and -tocopherol concentrations were determined at study entry and exit using high-performance liquid chromatography, while plasma total F2-isoprostanes, an index of oxidative stress, were measured using a commercially available enzyme-linked immunosorbent assay kit.
Results. ADMA and SDMA concentrations were significantly higher in the plasma of patients compared with that of controls (P 
0.001). After treatment with vitamin E, ADMA decreased by 23% in six of eight patients (P <0.001). The remaining two patients showed either an increase or no change (overall, P = 0.16). There was no significant change in plasma F2-isoprostanes with vitamin E treatment for 8 weeks.
Conclusions. Antioxidant therapy with vitamin E has the potential to lower ADMA levels in CKD patients, implying increased NO· availability. This strategy merits further exploration in the setting of CKD prior to renal replacement.
Keywords: asymmetric dimethylarginine (ADMA); chronic kidney disease; isoprostane; nitric oxide; -tocopherol; vitamin E
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. C. Richir, R. H. Bouwman, T. Teerlink, M. P.C. Siroen, T. P.G.M. de Vries, and P. A.M. van Leeuwen The Prominent Role of the Liver in the Elimination of Asymmetric Dimethylarginine (ADMA) and the Consequences of Impaired Hepatic Function JPEN J Parenter Enteral Nutr, November 1, 2008; 32(6): 613 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Desai, Y. Zhao, and J. S. Warren Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1513 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-L. Tain, G. Freshour, A. Dikalova, K. Griendling, and C. Baylis Vitamin E reduces glomerulosclerosis, restores renal neuronal NOS, and suppresses oxidative stress in the 5/6 nephrectomized rat Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1404 - F1410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Antoniades, D. Tousoulis, K. Marinou, C. Vasiliadou, C. Tentolouris, G. Bouras, C. Pitsavos, and C. Stefanadis Asymmetrical dimethylarginine regulates endothelial function in methionine-induced but not in chronic homocystinemia in humans: effect of oxidative stress and proinflammatory cytokines. Am. J. Clinical Nutrition, October 1, 2006; 84(4): 781 - 788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Zhao, S. Wang, H. Cheng, M.-z. Zhang, T. Takahashi, A. B. Fogo, M. D. Breyer, and R. C. Harris Endothelial Nitric Oxide Synthase Deficiency Produces Accelerated Nephropathy in Diabetic Mice J. Am. Soc. Nephrol., October 1, 2006; 17(10): 2664 - 2669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Carello, S. E. Whitesall, M. C. Lloyd, S. S. Billecke, and L. G. D'Alecy Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H209 - H216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Morimoto, K. Nakao, K. Fukuoka, A. Sarai, A. Yano, T. Kihara, S. Fukuda, J. Wada, and H. Makino Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2775 - 2782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Maas Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA) Vascular Medicine, July 1, 2005; 10(1_suppl): S49 - S57. [Abstract] [PDF]
|
|
|
|
|
|
T. Teerlink ADMA metabolism and clearance Vascular Medicine, July 1, 2005; 10(1_suppl): S73 - S81. [Abstract] [PDF]
|
|
|
|
 |
|
 A. R. Chade, A. Lerman, and L. O. Lerman Kidney in Early Atherosclerosis Hypertension, June 1, 2005; 45(6): 1042 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Maas Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA) Vascular Medicine, May 1, 2005; 10(2_suppl): S49 - S57. [Abstract] [PDF]
|
|
|
|
|
|
T. Teerlink ADMA metabolism and clearance Vascular Medicine, May 1, 2005; 10(2_suppl): S73 - S81. [Abstract] [PDF]
|
|
|
|
 |
|
 J. P. Cooke Asymmetrical Dimethylarginine: The Uber Marker? Circulation, April 20, 2004; 109(15): 1813 - 1818. [Full Text] [PDF]
|
|